WHAT IS CLAIMED IS:

1. A therapeutically effective amount of MK-0677 for use in the treatment of growth hormone deficiency (GHD) in children known to have short stature and equivalent growth potential compared to rhGH,

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

2. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein a single 0.8 mg/kg/d dose of MK-0677 is for oral administration.

3. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein MK-0677 is manufactured via at least one mini-tablets, comprising: MK-0677 for oral administration.

4. The therapeutically effective amount of MK-0677 foruse of Claim 3, wherein the mini-tablet, comprises: 2 mg of MK-0677.

5. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein the GHD is pediatric GHD.

6. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein MK-0677 is for oral administration with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

7. A therapeutically effective amount of MK-0677 for use in the treatment of GHD in children found from a theranostic test to have short stature and equivalent growth potential compared to rhGH;

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

8. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein a single, 0.8 mg/kg/d dose of MK-0677 is for oral administration.

9. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein MK-0677 is manufactured via at least one mini-tablet[s], comprising: MK-0677 for oral administration.

10. The therapeutically effective amount of MK-0677 for use of Claim 9, wherein the mini-tablet, comprises: 2 mg of MK-0677.

11. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein the therapeutically effective amount of MK-0677 is for oral administration with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

12. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein the GHD is pediatric GHD.

13. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein the children found from a theranostic test theranostic test to have short stature and equivalent growth potential compared to rhGH, comprises:

(i.) a peak serum GH of ≥5 μg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

14. The therapeutically effective amount of MK-0677 for use of Claim 13, wherein the single oral dose of MK-0677 is0.8 mg/kg/d .

15. A method of analyzing a drawn blood sample taken from subjects before and after being given a single oral dose of MK-0677, comprising:

(i.) testing for a peak serum GH ≥5 μg/L; and,

(ii.) testing a serum IGF-I wherein the drawn blood sample taken from subjects before being given a single oral dose of MK-0677 have serum IGF-I of >30ng/mL.

16. The method of Claim 15, wherein testing for peak serum, comprises:

a. testing the GH serum levels in blood samples taken from subjects at subsequent times after being given the single oral dose of MK-0677 to determine the peak serum GH level.

17. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

18. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

19. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

20. The therapeutically effective amount of MK-0677 for use of Claim 7, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

21. The therapeutically effective amount of MK-0677 for use of Claim 3, wherein the mini-tablet, comprises: 4 mg of MK-0677.

22. The therapeutically effective amount of MK-0677 for use of Claim 9, wherein the mini-tablet, comprises: 4 mg of MK-0677.

23. The therapeutically effective amount of MK-0677 for use of Claim 1, wherein the treatment is maintained for more than 6 months.

24. The therapeutically effective amount of MK-0677 for use of Claim 1, for treatment maintained for at least 7 months.

25. The therapeutically effective amount of MK-0677 for use of Claim 1, for treatment maintained until growth potential is exhausted.

26. The therapeutically effective amount of MK-0677 for use of Claim 7, for treatment maintained for more than 6 months.

27. The therapeutically effective amount of MK-0677 for use of Claim 7, for treatment maintained for at least 7 months.

28. The therapeutically effective amount of MK-0677 for use of Claim 7, for treatment maintained until growth potential is exhausted.